1. Introduction {#sec1}
===============

Clopidogrel is a commonly used antiplatelet agent, yet only several cases of hepatotoxicity have been described \[[@B1]--[@B16]\]. Liver biopsies were not performed in many of these cases. We report a rare case of severe clopidogrel-induced hepatitis with histological assessment.

2. Case Description {#sec2}
===================

A 34-year-old male with a history of coronary artery disease and remote coronary artery stent was placed on aspirin plus clopidogrel. His baseline liver biochemistries were normal. He had been on clopidogrel for 2 months 12 years ago without adverse effects but discontinued the medication on his own at that time due to nonadherence. Four and a half months after restarting clopidogrel, he presented with jaundice and fatigue. He denied fever, rash, arthralgias, or abdominal pain. His only other medications were aspirin and metoprolol, which he had been on for many years with normal liver biochemistries.

The patient was not on a statin. He denied recent alcohol or herbal medications. Physical examination was significant only for icterus. There was no hepatosplenomegaly, clubbing, rash, asterixis, or other stigmata of chronic liver disease.

Initial bilirubin was 5.7 mg/dL (normal 0.2--1.2 mg/dL), ALT 1,393 U/L (normal 7--48 U/L), AST 1,418 U/L (normal 7--48 U/L), alkaline phosphatase 130 U/L (normal 35--115 U/L), INR 1.5, and partial prothrombin time 37 seconds (normal 15--37 seconds). Extensive serologies were negative to hepatitis A, hepatitis B, hepatitis C (including hepatitis C RNA), hepatitis E, IgM to cytomegalovirus and Epstein-Barr virus, anti-nuclear antibody, anti-smooth muscle antibody, anti-mitochondrial antibody, anti-liver kidney microsomal antibody, and ceruloplasmin.

Imaging studies were negative, and bile ducts were not dilated, including by ultrasound, computed tomography, and endoscopic retrograde cholangiopancreatography. No gallstones were present on any imaging modality. Liver biopsy revealed severe acute hepatitis with mixed inflammatory portal tract infiltrates including plasma cells, neutrophils and eosinophils, bile ductular reaction, patchy hepatocyte ballooning degeneration, and extensive periportal hepatocyte dropout, without fibrosis ([Figure 1](#fig1){ref-type="fig"}).

The patient was diagnosed with clopidogrel-induced severe hepatitis. Despite discontinuing clopidogrel, AST increased to 2,107 U/L, ALT to 1,567 U/L, and bilirubin to 37 mg/dL (predominately direct bilirubin). INR had increased to 2.1 despite empiric administration of vitamin K. A brief course of prednisone and ursodiol was initiated, with subsequent normalization of liver biochemistries.

3. Discussion {#sec3}
=============

We describe a rare case of severe clopidogrel-induced hepatitis, with histological assessment. Our patient\'s drug-induced hepatitis was particularly severe with jaundice (peak bilirubin 37 mg/dL), marked elevation of transaminases (peak ALT of 1,567 U/L), and coagulopathy (INR 2.1). This degree of hepatic injury portends an increased mortality and underscores the importance of early recognition and discontinuation of the offending agent.

Clopidogrel-induced hepatitis has been described \[[@B1]--[@B16]\]. [Table 1](#tab1){ref-type="table"} lists reported cases in reverse chronological order. The degree of liver injury has ranged from reversible liver injury and recovery \[[@B1]--[@B9], [@B11]--[@B16]\] to acute hepatic failure and death \[[@B10]\]. Onset of liver injury in these cases ranges between 3 and 180 days \[[@B1]--[@B16]\]. Rechallenge confirmed clopidogrel-induced hepatitis in some of these cases \[[@B2]--[@B5]\]. Our patient\'s Naranjo scale and RUCAM (Roussel Uclaf Causality Assessment Method) scores were both 8, indicating probable drug-induced hepatitis \[[@B17], [@B18]\].

Our patients liver biopsy revealed severe hepatocellular injury. This adds to the histological findings in clopidogrel-induced hepatitis, as liver biopsy was only performed in 3 of the previously reported cases \[[@B1], [@B2], [@B11]\]. Clopidogrel-induced liver injury can be cholestatic, hepatocellular \[[@B11]\], or mixed hepatocellular plus cholestatic \[[@B1], [@B2]\].

The exact mechanism of clopidogrel-induced hepatitis is unclear. The delayed onset of 4.5 months in our case suggests a toxic-metabolic etiology, whereas the inflammatory infiltrate and response to corticosteroids raise the possibility of a superimposed immune mediated mechanism of injury. Clopidogrel is a prodrug which is metabolized to inactive clopidogrel carboxylate (90%) and an active metabolite containing a mercapto group (10%) by cytochrome P450 3A4 and 2C19. In vitro studies suggest that the active metabolite is responsible for the hepatotoxicity and that high cytochrome 3A4 activities coupled with cellular glutathione depletion are potential risk factors \[[@B19]\]. Interestingly, an earlier antiplatelet agent, ticlopidine, has also been reported to cause drug-induced cholestatic hepatitis \[[@B20], [@B21]\].

Clopidogrel-induced hepatitis is a rare but potentially serious adverse effect. A high degree of clinical suspicion is required in patients presenting with abnormal liver biochemistries within a few months after starting clopidogrel. Prompt recognition and discontinuation of the offending agent are necessary, as progressive liver injury and even death can occur.
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![Liver biopsy showing severe acute hepatitis with mixed inflammatory portal tract infiltrate (white arrow), patchy hepatocyte ballooning degeneration (black arrow), and extensive periportal hepatocyte dropout (grey arrow).](CRIHEP2016-8068276.001){#fig1}

###### 

Clopidogrel-induced hepatitis: reported cases.

  Cases                                                            Latency/onset           Peak ALT (U/L)   Peak bilirubin (mg/dL)   Peak alkaline phosphatase (U/L)   Symptoms                                                  Histology                                                                    Outcome
  ---------------------------------------------------------------- ----------------------- ---------------- ------------------------ --------------------------------- --------------------------------------------------------- ---------------------------------------------------------------------------- ----------
  Keshmiri et al. 2016 (current)                                   135 days (4.5 months)   1567             37                       130                               Jaundice, fatigue                                         Hepatocellular                                                               Recovery
  Kapila et al. 2015 \[[@B9]\]                                     5 days                  716              1.6                      160                               Nausea, vomiting, fever                                   No liver biopsy                                                              Recovery
  Pisapia et al. 2015 \[[@B2]\]                                    3 days                  1603             24.5                     408                               Jaundice, arthralgia, papular rash                        Mixed hepatocellular and cholestatic                                         Recovery
  Monteiro et al. 2011 \[[@B13]\]                                  30 days                 540              3.5                      139                               Nausea, vomiting                                          No liver biopsy                                                              Recovery
  Leighton et al. 2011 \[[@B11]\]                                  1 day                   3626             3.3                      364                               Anorexia, jaundice, epigastric pain                       Lymphoplasmacytic portal, interface and lobular hepatitis with no fibrosis   Recovery
  Kastalli et al. 2010 \[[@B10]\]                                  19 days                 336              4.7                      186                               Jaundice, abdominal pain                                  No liver biopsy                                                              Death
  Goyal et al. 2009 \[[@B3]\]                                      23 days                 1011             7.3                      1011                              Abdominal pain, anorexia, jaundice                        No liver biopsy                                                              Recovery
  Wiper et al. 2008 \[[@B4]\]                                      60 days                 450              Normal                   680                               General malaise                                           No liver biopsy                                                              Recovery
  L$\acute{o}$pez-Vicente et al. 2007 \[[@B12]\]                   30 days                 204              1.0                      682                               Abdominal pain, fever                                     No liver biopsy                                                              Recovery
  Ng et al. 2006 \[[@B5]\]                                         3 days                  536              1.5                      247                               Fever, chills                                             No liver biopsy                                                              Recovery
  H$\overset{¨}{o}$llm$\overset{¨}{u}$ller et al. 2006 \[[@B1]\]   43 days                 1003             20.8                     221                               Weight loss, anorexia, jaundice, nausea, abdominal pain   Mixed hepatocellular and cholestatic                                         Recovery
  Chau et al. 2005 \[[@B7]\]                                       37 days                 253              6.9                      172                               Jaundice                                                  No liver biopsy                                                              Recovery
  Beltran-Robles et al. 2004 \[[@B6]\]                             4 days                  318              0.51                     100                               No symptoms mentioned                                     No liver biopsy                                                              Recovery
  Wolf et al. 2003 \[[@B16]\]                                      12 days                 173              1.3                      132                               Fever, leukopenia, weakness                               No liver biopsy                                                              Recovery
  Ramos Ramos et al. 2003 \[[@B14]\]                               60 days                 710              24.9                     118                               Jaundice                                                  No liver biopsy                                                              Recovery
  Duran-Quintana et al. 2002 \[[@B8]\]                             180 days                786              13                       474                               Icterus, hepatomegaly                                     No liver biopsy                                                              Recovery
  Willens 2000 \[[@B15]\]                                          21 days                 507              3.0                      636                               Malaise, anorexia, myalgia, icterus                       No liver biopsy                                                              Recovery
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